• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form FWP filed by Global Medical REIT Inc.

    11/14/25 6:01:45 AM ET
    $GMRE
    Real Estate Investment Trusts
    Real Estate
    Get the next $GMRE alert in real time by email
    FWP 1 tm2531263d1_fwp.htm FWP

     

    Issuer Free Writing Prospectus

    Filed Pursuant to Rule 433

    Relating to Preliminary Prospectus Supplement dated November 13, 2025

    to Prospectus dated April 4, 2024

    Registration No. 333-276248

     

    PRICING TERM SHEET

     

    8.00% Series B Cumulative Redeemable Preferred Stock
    (Liquidation Preference $25.00 per Share)

     

    November 13, 2025

     

    Issuer: Global Medical REIT Inc., a Maryland corporation
    Security: 8.00% Series B Cumulative Redeemable Preferred Stock
    Number of Shares: 2,000,000 shares (2,300,000 shares if the underwriters’ over-allotment option to purchase additional shares is exercised in full)
    Public Offering Price: $25.00 per share; $50,000,000 total (not including the underwriters’ over-allotment option to purchase additional shares)
    Underwriting Discounts: $0.7875 per share; $1,575,000 total (not including the underwriters’ over-allotment option to purchase additional shares)
    Maturity Date: Perpetual (unless redeemed by the Issuer on or after November 20, 2030 or pursuant to its special optional redemption right, or converted by a holder in connection with a change of control described below under “Change of Control”)
    Trade Date: November 13, 2025
    Settlement Date: November 20, 2025 (T + 5)
    Liquidation Preference: $25.00, plus accrued and unpaid dividends
    Dividend Rate: 8.00% per annum of the $25.00 per share liquidation preference (equivalent to $2.00 per annum per share), accruing from November 20, 2025
    Dividend Payment Dates: Quarterly in arrears on January 31, April 30, July 31 and October 31 of each year, commencing on January 31, 2026, to holders of record as of January 15, 2026; the first dividend will be paid on February 2, 2026 since January 31, 2026 is not a business day
    Optional Redemption:

    The Issuer may not redeem the Series B Preferred Stock prior to November 20, 2030, except in limited circumstances to preserve its status as a real estate investment trust and pursuant to the special optional redemption provision described below under “Special Optional Redemption.”

     

    The Issuer may, at its option, redeem the Series B Preferred Stock for cash, in whole or in part, from time or from time to time, at any time, on or after November 20, 2030 at a redemption price equal to $25.00 per share, plus any accumulated and unpaid dividends up to (whether or not authorized or declared), if any, to, but excluding, the date of redemption.

    Special Optional Redemption: Upon the occurrence of a Change of Control (as defined below), the Issuer may, at its option, redeem the Series B Preferred Stock for cash, in whole or in part, within 120 days after the date on which such Change of Control occurred, by paying $25.00 per share, plus any accumulated and unpaid dividends (whether or not authorized or declared), if any, to, but excluding, the date of redemption. If, prior to the Change of Control Conversion Date (as defined below), the Issuer has provided or provides notice of its election to redeem the Series B Preferred Stock (whether pursuant to the optional redemption right or the special redemption option), the holders of Series B Preferred Stock will not be permitted to exercise the conversion right described below with respect to the shares subject to such notice.

     

     

     

     

    Change of Control:

    A “Change of Control” means, after the original issuance of the Series B Preferred Stock, the following have occurred and are continuing:

     

    ·      the acquisition by any person, including any syndicate or group deemed to be a “person” under Section 13(d)(3) of the Securities Exchange Act of 1934, as amended, of beneficial ownership, directly or indirectly, through a purchase, merger or other acquisition transaction or series of purchases, mergers, conversions or other acquisition transactions of shares of the Issuer’s stock entitling that person to exercise more than 50% of the total voting power of all stock of the Issuer entitled to vote generally in the election of the Issuer’s directors (except that the person will be deemed to have beneficial ownership of all securities that the person has the right to acquire, whether the right is currently exercisable or is exercisable only upon the occurrence of a subsequent condition); and

     

    ·      following the closing of any transaction referred to in the bullet point above, neither the Issuer nor the acquiring or surviving entity has a class of common equity securities listed on the New York Stock Exchange (the “NYSE”), the NYSE American, LLC (the “NYSE American”) or the Nasdaq Stock Market (“Nasdaq”), or listed or quoted on an exchange or quotation system that is a successor to the NYSE, the NYSE American or Nasdaq.

     

    Notwithstanding the foregoing, if the transaction or series of transactions described in the first bullet point above (the “Change of Control Transaction”) forms part of a series of related transactions that are closed or consummated within twelve (12) months of the closing or consummation of the Change of Control Transaction (including, without limitation, any merger, consolidation, sale or transfer of assets, recapitalization, reorganization, or special or extraordinary distribution, in each case outside of the ordinary course of the Issuer’s business (the “Related Transactions”)), and if the aggregate consideration paid to the Issuer and/or holders of its common stock in connection with the Change of Control Transaction represents less than 50.0% of the aggregate consideration payable to the Issuer and/or its holders of common stock in connection with both the Change of Control Transaction and the Related Transaction on a combined basis, then the Change of Control Transaction shall be deemed to constitute a Change of Control, regardless of whether the second bullet point above is satisfied

     

     

     

     

    Conversion Rights:

    Upon the occurrence of a Change of Control, each holder of Series B Preferred Stock will have the right (unless, prior to the Change of Control Conversion Date, the Issuer has provided or provides notice of its election to redeem the Series B Preferred Stock in whole or in part) to convert some or all of the Series B Preferred Stock held by such holder on the Change of Control Conversion Date into a number of shares of the Issuer’s common stock per share of Series B Preferred Stock to be converted equal to the lesser of:

    ·     the quotient obtained by dividing (i) the sum of (x) the liquidation preference amount of $25.00 per share of Series B Preferred Stock, plus (y) the amount of any accrued and unpaid dividends (whether or not declared) to, but excluding, the Change of Control Conversion Date (unless the Change of Control Conversion Date is after a record date for a Series B Preferred Stock dividend payment for which dividends have been declared and prior to the corresponding Series B Preferred Stock dividend payment date, in which case no additional amount for such accrued and unpaid dividend will be included in this sum and such declared dividend will instead be paid, on such dividend payment date, to the holder of record of the shares of Series B Preferred Stock to be converted as of 5:00 p.m. New York City time, on such record date) by (ii) the Common Stock Price; and

     

    ·      1.55666 (i.e., the Share Cap), subject to certain adjustments;

    subject, in each case, to provisions for the receipt of alternative consideration as described in the preliminary prospectus supplement.

     

    The Share Cap is subject to pro rata adjustments for any share splits (including those effected pursuant to a distribution of the Issuer’s common stock), subdivisions or combinations with respect to the Issuer’s common stock as described in the preliminary prospectus supplement.

     

    Upon such a conversion, the holders will be limited to a maximum number of shares of the Issuer’s common stock equal to the lesser of (i) the conversion value (equal to the liquidation preference and unpaid and accrued dividends), divided by the closing price on the date of the event triggering the Change of Control and (ii) the Share Cap, subject to adjustments, which may result in a holder receiving value that is less than the liquidation preference of the Series B Preferred Stock.

     

    If, prior to the Change of Control Conversion Date, the Issuer has provided or provides a redemption notice (whether pursuant to the special optional redemption right or its special redemption option), holders of Series B Preferred Stock will not be permitted to convert the shares of the Series B Preferred Stock selected for redemption in connection with the Change of Control Conversion.

     

    The “Change of Control Conversion Date” is the date on which the shares of Series B Preferred Stock are to be converted, which will be a business day that is no fewer than 20 days nor more than 35 days after the date on which the Issuer provides the required notice of the occurrence of a Change of Control to the holders of shares of Series B Preferred Stock.

     

    The “Common Stock Price” will be (i) if the consideration to be received in the Change of Control by the holders of the Issuer’s common stock is solely cash, the amount of cash consideration per share of the Issuer’s common stock or (ii) if the consideration to be received in the Change of Control by holders of the Issuer’s common stock is other than solely cash (x) the average of the closing sale prices per share of the Issuer’s common stock (or, if no closing sale price is reported, the average of the closing bid and ask prices or, if more than one in either case, the average of the average closing bid and the average closing ask prices) for the 10 consecutive trading days immediately preceding, but not including, the effective date of the Change of Control as reported on the principal U.S. securities exchange on which the Issuer’s common stock is then traded, or (y) the average of the last quoted bid prices for the Issuer’s common stock in the over-the-counter market as reported by OTC Markets Group Inc. or similar organization for the 10 consecutive trading days immediately preceding, but not including, the effective date of the Change of Control, if the Issuer’s common stock is not then listed for trading on a U.S. securities exchange

     

     

     

     

    CUSIP/ISIN: 37954A402  / US37954A4022
    Joint Book-Running Managers:

    Raymond James & Associates, Inc.

    BMO Capital Markets Corp.

    Stifel, Nicolaus & Company, Incorporated

    Robert W. Baird & Co. Incorporated

    Co-Managers:

    Janney Montgomery Scott LLC
    B. Riley Securities, Inc.

    Ladenburg Thalmann & Co. Inc
    Berenberg Capital Markets LLC
    Colliers Securities LLC

    Listing: The Issuer intends to file an application to list the Series B Preferred Stock on the NYSE under the symbol “GMRE-PrB”. If the application is approved, trading of the Series B Preferred Stock on the NYSE is expected to begin within 30 days after the Series B Preferred Stock is first issued.

     

    This communication is intended for the sole use of the person to whom it is provided by the sender.

     

    The Issuer has filed a registration statement (including a prospectus and a prospectus supplement) with the Securities and Exchange Commission (“SEC”) for the offering to which this communication relates. Before you invest, you should read the base prospectus and prospectus supplement in that registration statement and other documents the Issuer has filed with the SEC for more complete information about the Issuer and this offering. You may get these documents for free by visiting EDGAR on the SEC web site at www.sec.gov. Alternatively, the Issuer, any underwriter or any dealer participating in the offering will arrange to send you the prospectus and prospectus supplement if you request it by contacting Raymond James & Associates, Inc., Attention: Equity Syndicate, 880 Carillon Parkway, St. Petersburg, Florida 33716, by telephone at (800) 248-8863, or by email at [email protected]; BMO Capital Markets Corp., Attn: Equity Syndicate Department, 151 W 42nd Street, 32nd Floor, New York, NY 10036, or by email at [email protected]; Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate Department, 1201 Wills Street, Suite 600, Baltimore, MD 21231, or by email at [email protected]; and Robert W. Baird & Co. Incorporated, Attention: Syndicate Department, 777 E. Wisconsin Avenue, Milwaukee, WI 53202, telephone: 800-792-2473, email: [email protected].

     

     

     

     

    Get the next $GMRE alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GMRE

    DatePrice TargetRatingAnalyst
    10/13/2025$40.00Mkt Perform → Mkt Outperform
    Citizens JMP
    4/3/2025$9.00Neutral
    B. Riley Securities
    10/18/2024$11.75Buy
    Berenberg
    9/19/2024$12.00Buy
    Alliance Global Partners
    10/10/2022$9.00Outperform → Neutral
    Robert W. Baird
    10/6/2022$13.00 → $9.00Outperform → Market Perform
    BMO Capital Markets
    7/7/2022Mkt Perform
    JMP Securities
    1/13/2022Overweight → Sector Weight
    Keybanc
    More analyst ratings

    $GMRE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CFO and Treasurer Kiernan Robert J bought $95,730 worth of shares (3,000 units at $31.91) (SEC Form 4)

    4 - Global Medical REIT Inc. (0001533615) (Issuer)

    11/17/25 8:09:35 PM ET
    $GMRE
    Real Estate Investment Trusts
    Real Estate

    CEO and President Decker Mark Okey Jr bought $325,813 worth of shares (10,000 units at $32.58), increasing direct ownership by 29% to 44,774 units (SEC Form 4)

    4 - Global Medical REIT Inc. (0001533615) (Issuer)

    11/17/25 8:08:59 PM ET
    $GMRE
    Real Estate Investment Trusts
    Real Estate

    Director Cypher Matthew bought $9,960 worth of shares (1,350 units at $7.38) (SEC Form 4)

    4 - Global Medical REIT Inc. (0001533615) (Issuer)

    8/26/25 5:13:35 PM ET
    $GMRE
    Real Estate Investment Trusts
    Real Estate

    $GMRE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CFO and Treasurer Kiernan Robert J bought $95,730 worth of shares (3,000 units at $31.91) (SEC Form 4)

    4 - Global Medical REIT Inc. (0001533615) (Issuer)

    11/17/25 8:09:35 PM ET
    $GMRE
    Real Estate Investment Trusts
    Real Estate

    CEO and President Decker Mark Okey Jr bought $325,813 worth of shares (10,000 units at $32.58), increasing direct ownership by 29% to 44,774 units (SEC Form 4)

    4 - Global Medical REIT Inc. (0001533615) (Issuer)

    11/17/25 8:08:59 PM ET
    $GMRE
    Real Estate Investment Trusts
    Real Estate

    Director Cypher Matthew bought $9,960 worth of shares (1,350 units at $7.38) (SEC Form 4)

    4 - Global Medical REIT Inc. (0001533615) (Issuer)

    8/26/25 5:13:35 PM ET
    $GMRE
    Real Estate Investment Trusts
    Real Estate

    $GMRE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Global Medical REIT upgraded by Citizens JMP with a new price target

    Citizens JMP upgraded Global Medical REIT from Mkt Perform to Mkt Outperform and set a new price target of $40.00

    10/13/25 8:40:10 AM ET
    $GMRE
    Real Estate Investment Trusts
    Real Estate

    B. Riley Securities resumed coverage on Global Medical REIT with a new price target

    B. Riley Securities resumed coverage of Global Medical REIT with a rating of Neutral and set a new price target of $9.00

    4/3/25 8:18:01 AM ET
    $GMRE
    Real Estate Investment Trusts
    Real Estate

    Berenberg initiated coverage on Global Medical REIT with a new price target

    Berenberg initiated coverage of Global Medical REIT with a rating of Buy and set a new price target of $11.75

    10/18/24 7:31:30 AM ET
    $GMRE
    Real Estate Investment Trusts
    Real Estate

    $GMRE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Global Medical REIT Inc. Announces Pricing of Public Offering of 8.00% Series B Preferred Stock

    Global Medical REIT Inc. (NYSE:GMRE) (the "Company") today announced the pricing of the underwritten public offering of 2,000,000 shares of its 8.00% Series B Cumulative Redeemable Preferred Stock, $0.001 par value per share ("Series B Preferred Stock"). The Series B Preferred Stock has an initial liquidation preference of $25.00 per share. The offering is expected to close on November 20, 2025, subject to customary closing conditions. The Company expects to receive gross proceeds of approximately $50,000,000, before deducting underwriting discounts and commissions and estimated offering expenses. The Company has granted the underwriters a 30-day option to purchase up to an additional 300,0

    11/13/25 10:30:00 PM ET
    $GMRE
    Real Estate Investment Trusts
    Real Estate

    Global Medical REIT Inc. Announces Proposed Public Offering of Series B Preferred Stock

    Global Medical REIT Inc. (NYSE:GMRE) (the "Company") today announced the commencement of an underwritten public offering of shares of its Series B Cumulative Redeemable Preferred Stock, $0.001 par value per share ("Series B Preferred Stock"), subject to market and other conditions. The Company expects to grant the underwriters a 30-day option to purchase additional shares of Series B Preferred Stock to cover over-allotments, if any. The Company intends to use the net proceeds from the offering for general corporate purposes, which may include funding new acquisitions and repaying indebtedness, including amounts outstanding under the Company's credit facility. The Company intends to apply

    11/13/25 8:39:00 AM ET
    $GMRE
    Real Estate Investment Trusts
    Real Estate

    Global Medical REIT Announces Third Quarter 2025 Financial Results

    – Amends and Restates Credit Facility – – Completes One-for-Five Reverse Stock Split and Establishes $50 Million Share Repurchase Program – Global Medical REIT Inc. (NYSE:GMRE) (the "Company" or "GMRE"), today announced financial results for the three and nine months ended September 30, 2025 and other data. NOTE: All share and per share data have been adjusted for all periods presented to reflect the Company's one-for-five reverse stock split that was effective September 19, 2025. Third Quarter 2025 and Other Highlights Net loss attributable to common stockholders was $6.0 million, or $0.45 per diluted share, as compared to net income of $1.8 million, or $0.14 per diluted share, in th

    11/4/25 4:05:00 PM ET
    $GMRE
    Real Estate Investment Trusts
    Real Estate

    $GMRE
    SEC Filings

    View All

    SEC Form CERT filed by Global Medical REIT Inc.

    CERT - Global Medical REIT Inc. (0001533615) (Filer)

    11/18/25 4:56:18 PM ET
    $GMRE
    Real Estate Investment Trusts
    Real Estate

    SEC Form 8-A12B filed by Global Medical REIT Inc.

    8-A12B - Global Medical REIT Inc. (0001533615) (Filer)

    11/18/25 4:22:25 PM ET
    $GMRE
    Real Estate Investment Trusts
    Real Estate

    Global Medical REIT Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

    8-K - Global Medical REIT Inc. (0001533615) (Filer)

    11/18/25 4:15:41 PM ET
    $GMRE
    Real Estate Investment Trusts
    Real Estate

    $GMRE
    Leadership Updates

    Live Leadership Updates

    View All

    Ortelius Director Nominees Release Joint Letter to Brookdale Stockholders

    Ortelius Nominees Believe Brookdale Offers a Tremendous Value Creation Opportunity Under a Renewed Board and New Strategic Roadmap Six Highly Qualified and Independent Nominees Will Act with Urgency, Integrity, and Transparency to Increase Value for Stockholders Brookdale Stockholders are Urged to Vote the WHITE Proxy Card FOR all Six Ortelius Nominees Ortelius Advisors, L.P. ("Ortelius") today announced that the six highly qualified individuals nominated by Ortelius for election to the Board of Directors (the "Board") of Brookdale Senior Living Inc. (NYSE:BKD) ("Brookdale" or the "Company") at the upcoming 2025 Annual Meeting of Stockholders released a joint letter to Brookdale stock

    7/3/25 8:00:00 AM ET
    $BKD
    $GMRE
    $NTST
    Hospital/Nursing Management
    Health Care
    Real Estate Investment Trusts
    Real Estate

    Global Medical REIT Appoints Mark Decker, Jr. as CEO

    Global Medical REIT Inc. (NYSE:GMRE) (the "Company" or "GMRE"), today announced that Mark Decker, Jr. has been appointed as the Company's Chief Executive Officer and President, effective immediately. Mr. Decker, who will join the Board of Directors, succeeds Jeffrey Busch, who will continue to serve on the Board as non-executive Chairman. Lori Wittman, Lead Independent Director of the Company stated, "We are extremely pleased to announce Mark Decker, Jr. as our new Chief Executive Officer. As part of the Board's ongoing commitment and efforts to maximize shareholder value, we identified the need for a fresh, strategic perspective to guide our portfolio management and growth initiatives. M

    6/23/25 7:00:00 AM ET
    $CSR
    $GMRE
    Real Estate Investment Trusts
    Real Estate

    Global Medical REIT Announces Succession Plan

    Chief Executive Officer Transition Expected in 2025 Mr. Busch to Remain on Board of Directors as Non-Executive Chairman Lori Wittman Appointed Lead Independent Director Effective January 1, 2025 Global Medical REIT Inc. (NYSE:GMRE) (the "Company" or "GMRE"), a net-lease medical real estate investment trust (REIT) that acquires healthcare facilities and leases those facilities to physician groups and regional and national healthcare systems, today announced that as part of the Company's succession planning efforts, the Board of Directors (the "Board") has reached an agreement with Mr. Jeffrey Busch, Chairman of the Board of Directors and Chief Executive Officer ("CEO") of the Company,

    1/8/25 4:15:00 PM ET
    $GMRE
    Real Estate Investment Trusts
    Real Estate

    $GMRE
    Financials

    Live finance-specific insights

    View All

    Global Medical REIT Announces Third Quarter 2025 Financial Results

    – Amends and Restates Credit Facility – – Completes One-for-Five Reverse Stock Split and Establishes $50 Million Share Repurchase Program – Global Medical REIT Inc. (NYSE:GMRE) (the "Company" or "GMRE"), today announced financial results for the three and nine months ended September 30, 2025 and other data. NOTE: All share and per share data have been adjusted for all periods presented to reflect the Company's one-for-five reverse stock split that was effective September 19, 2025. Third Quarter 2025 and Other Highlights Net loss attributable to common stockholders was $6.0 million, or $0.45 per diluted share, as compared to net income of $1.8 million, or $0.14 per diluted share, in th

    11/4/25 4:05:00 PM ET
    $GMRE
    Real Estate Investment Trusts
    Real Estate

    Global Medical REIT Inc. Announces Dates for 2025 Third Quarter Earnings Release and Webcast

    Global Medical REIT Inc. (NYSE:GMRE) (the "Company" or "GMRE"), announced today that it intends to release its third quarter 2025 financial results after the market closes on Tuesday, November 4, 2025. The Company intends to hold a conference call to discuss those results the following day, Wednesday, November 5, 2025, at 9:00 a.m. Eastern Time. The conference call will be hosted by President and Chief Executive Officer Mark Decker, Jr., Chief Financial Officer Robert Kiernan, Chief Investment Officer Alfonzo Leon and Chief Operating Officer Danica Holley. Webcast Information Participants may access the call via live webcast by visiting the investor information section of the Company's

    10/15/25 4:05:00 PM ET
    $GMRE
    Real Estate Investment Trusts
    Real Estate

    Global Medical REIT Inc. Amends and Restates Credit Facility

    – Extends Loan Maturities and Enters into Forward Starting Interest Rate Swaps to Hedge Term Loans – – Weighted Average Term of the Company's Debt Increases from 1.3 Years to 4.4 Years – Global Medical REIT Inc. (NYSE:GMRE) (the "Company" or "GMRE") today announced that it entered into an amended and restated credit facility (the "Amended and Restated Credit Facility") that extends the maturities of its borrowings and, among other things, includes the following terms: Extends the initial maturity date of the existing $400 million revolver component of the credit facility to October 2029 with two, six-month extension options available at the Company's election to extend the maturity t

    10/8/25 4:05:00 PM ET
    $GMRE
    Real Estate Investment Trusts
    Real Estate

    $GMRE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Global Medical REIT Inc. (Amendment)

    SC 13G/A - Global Medical REIT Inc. (0001533615) (Subject)

    1/25/24 4:59:30 PM ET
    $GMRE
    Real Estate Investment Trusts
    Real Estate

    SEC Form SC 13G/A filed by Global Medical REIT Inc. (Amendment)

    SC 13G/A - Global Medical REIT Inc. (0001533615) (Subject)

    2/9/23 11:19:25 AM ET
    $GMRE
    Real Estate Investment Trusts
    Real Estate

    SEC Form SC 13G/A filed by Global Medical REIT Inc. (Amendment)

    SC 13G/A - Global Medical REIT Inc. (0001533615) (Subject)

    1/31/23 1:58:04 PM ET
    $GMRE
    Real Estate Investment Trusts
    Real Estate